EUVIMEDEUVIMED entdecken
Open Access

New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023

Ian Hennessee, Kaitlin Benedict iD, Dallas J Smith iD, Nicolas Barros

Mycoses · 2025

DOI: 10.1111/myc.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, 2025. Verfasst von Ian Hennessee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Histoplasmosis, Asthma, Adrenergic beta-2 Receptor Agonists. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although several fungal infections have been linked to asthma development, the relationship between histoplasmosis and asthma development has not been fully described.

Objectives

To assess the incidence of new asthma diagnosis codes or short‐acting β 2 agonist (SABA) prescription in the year following histoplasmosis diagnosis and identify potentially related factors.

Methods

We used a large health insurance claims database to identify patients with histoplasmosis with and without an asthma diagnosis code or a short‐acting β 2 agonist prescription in the year after diagnosis.

Results

Among 1819 patients diagnosed with histoplasmosis, 252 (13.9%) received a new asthma diagnosis or SABA prescription in the subsequent year, more than double the proportion in the general population (5.8%). Pulmonary histoplasmosis and symptoms such as dyspnea and wheezing were associated with asthma diagnosis or SABA receipt.

Conclusion

These findings suggest that histoplasmosis may predispose certain patients to airway hyperreactivity, particularly those with acute pulmonary symptoms. Further research is needed to elucidate potential mechanisms underlying these findings, which could inform strategies to mitigate post‐infectious airway disease in affected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistoplasmosisAsthmaAdrenergic beta-2 Receptor AgonistsHumansUnited StatesMaleFemaleMiddle AgedAdultInsurance, HealthAgedYoung AdultIncidenceDatabases, FactualAdolescentDrug Prescriptions

Stichwörter der Autor:innen

United Statesasthmahealth insurancehistoplasmosis

Substanzen

Adrenergic beta-2 Receptor Agonists

Autor:innen und Institutionen

  • Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Kaitlin Benedict, Dallas J Smith

Förderung

  • Intramural CDC HHS

Zitieren

APA

Hennessee, I., Benedict, K., Smith, D. J., & Barros, N. (2025). New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023. Mycoses. https://doi.org/10.1111/myc.70109

Vancouver

Hennessee I, Benedict K, Smith DJ, Barros N. New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023. Mycoses. 2025. doi:10.1111/myc.70109

BibTeX
@article{Hennessee2025,
  author = {Hennessee, Ian and Benedict, Kaitlin and Smith, Dallas J and Barros, Nicolas},
  title = {New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023},
  journal = {Mycoses},
  year = {2025},
  doi = {10.1111/myc.70109}
}
Kostenlos starten →